Compare Crispr Therapeutics AG (CRSP) vs PPG Industries, Inc. (PPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs PPG Industries, Inc. — how do they compare? Crispr Therapeutics AG trades at $50.94 (market cap $4.88B), while PPG Industries, Inc. trades at $105.05 (market cap $23.44B). The key difference: PPG Industries, Inc. is far larger — about 4.8× Crispr Therapeutics AG's market cap, and PPG Industries, Inc. pays a 2.81% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and PPG Industries, Inc. for 68 Days on average.
| CRSP | PPG | |
|---|---|---|
Market Cap | $4.88B | $23.44B |
Volume | 2,861,747 | 2,064,777 |
Sector | Health | Basic Materials |
52-Week High | $74.92 | $131.56 |
52-Week Low | $44.34 | $94.34 |
Typical Hold Time | 77 Days | 68 Days |
Enterprise Value | $3.30B | $29.31B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
PPG trades at $105.08, down 1.37% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported mixed quarterly earnings, with a Q2 2026 EPS miss of $2.23 vs. $2.25 expected, though Q1 2026 beat expectations. Fundamentals show a P/E of 15.13, net income margin of 9.57%, and strong cash flow from operations of $1.94B in 2025. Recent news highlights margin pressures in the Automotive Refinish segment but innovation efforts in marine coatings.
The outlook is cautiously optimistic, with a consensus price target of $130 implying 24% upside, supported by 55% analyst buy ratings. Risks include segment-specific weakness and macroeconomic headwinds, but valuation remains reasonable with solid profitability. The stock offers a dividend yield from its upcoming $0.74 payout, appealing for income-focused investors amid ongoing cost management initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →
